Biocon CEO Arun Chandavarkar says Sandoz tie-up to help them target multi-billion dollar biosimilar opportunity

作者:ANASTASIA 時間:2018-01-22 17:46:03 標籤: 分類:

Viswanath Pilla
Moneycontrol News 


Biocon

and Sandoz, a division of Swiss-pharmaceutical major Novartis, on Thursday announced that they have entered into a global partnership to develop, manufacture and commercialise multiple biosimilars in immunology and oncology for patients across the globe. In an email interview to Moneycontrol, Biocon Chief Executive Officer and Joint Managing Director Arun Chandavarkar provided insights into what this deal means for Biocon as it aims for a pie of multi-billion dollar global biosimilar business.

Excerpts from the interview:

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ".moneycontrol.com"});

What are the broad contours of the biosimilars co-development deal between Biocon and Sandoz?
This is an exclusive global collaboration between the two companies wherein both will share responsibility for end to end development, manufacturing and global regulatory approvals for a number of biosimilar products, and will have a cost and profit share arrangement globally. The collaboration will leverage the combined strengths of the two companies in development, manufacturing and commercialisation of biosimilars.


How many products will you be co-developing and for which therapy areas?
The collaboration aims to co-develop a set of identified high-quality, affordable immunology and oncology biologics, complementing our current biosimilars portfolio. It provides foundation for expansion of the portfolio.


What are the financial terms of the deal?

Under the terms of the agreement, both companies will share responsibility for end-to-end development, manufacturing and global regulatory approvals for a number of products and will have a cost and profit share arrangement globally. Worldwide commercialisation responsibilities will be divided and each company’s strengths will be leveraged within specific geographies. Sandoz will lead commercialisation in North America, including the US and Canada, and EU, including European Free Trade Association and Balkan states, while Biocon will lead commercialisation in Rest of the World, including India, Russia and Commonwealth of Independent States (CIS).

date = new Date(); date.setTime(date.getTime()+(1*24*60*60*1000)); $.cookie("dfp_cookie_article", "Y1", {expires: date,path:"/",domain: ".moneycontrol.com"});

related news

HDFC Bank reports divergence of Rs 2,051 cr for FY17; profits grow 20%

Jubilant FoodWorks appoints Prakash C Bisht as CFO

Honda recalls 22,834 cars across various models in India

What is the combined market potential of these multiple biosimilars?

The partnership will address a multi-billion dollar global opportunity.

When do the patents expire for these products?

We are targeting opportunities that are expected to open up in the next decade.

Will the development costs for these biosimilars start reflecting on Biocon’s P&L?

These biosimilars are in early stages of development. As the cost incurred during the early stages are not significant we don』t expect our R&D costs to go up materially as of now.

What led Biocon to team up with Sandoz for developing these biosimilars?

Biocon is committed to provide affordable access to advanced biopharmaceuticals for global patient populations. We are developing advanced therapies that have the potential to benefit billions of patients, thus making healthcare both more effective and more equitable around the world. Along with Sandoz, we share a long-term commitment to increase patient access to high-quality biosimilars.

After successfully partnering Mylan, our collaboration with Sandoz is part of our journey of moving up the value chain. In this partnership, Biocon will get an opportunity to participate not only in end to end development and manufacturing of the partnered products but also in obtaining regulatory approvals and commercializing them in the chosen geographies.

This collaboration is also in keeping with Biocon's long-term strategy of targeting the global opportunity offered by the next wave of biosimilar products.

What does the agreement with Sandoz mean for Biocon’s existing collaboration with Mylan?

The biosimilars being developed under the Biocon and Sandoz partnership is outside the portfolio being developed with Mylan and we are confident that this collaboration will be equally strong and meaningful in furthering our shared vision of expanding access to affordable biologics for patients globally.

Biocon and Mylan have one of the longest-standing partnerships in the global biosimilars space. We have leveraged our mutual strengths to build one of the largest and most diverse biosimilar pipelines, spanning biosimilar monoclonal antibodies, other recombinant proteins, and insulin analogs. We continue to work closely in advancing some of these products to be commercialised in various developed markets. We immensely value our partnership with Mylan and believe our joint portfolio will deliver near term value growth for us.

Are you aware if other global biosimilars players are also working on the same drugs that Biocon and Sandoz are collaborating on?

While we cannot comment on the pipelines of other companies, we believe there will be competition. However, given that biosimilars is a complex area with high entry barriers there will be a limited number of players, which makes it an attractive opportunity – and by beginning our work together now, we continue to be ahead of competition.


本文來源:http://www.moneycontrol.com/news/business/companies/biocon-ceo-arun-chandavarkar-says-sandoz-tie-up-to-help-them-target-multi-billion-dollar-biosimilar-opportunity-2486943.html

Apr. 10th 2016

如何選擇美容機構

美容

我們在選擇美容減肥機構之前,就應該更充分了解美容機構好不好的問題,比如美哪家美容中心好。

Apr. 15th 2016

食療養生

養生

如何進行正確的食療養生呢?一個最簡單的方法就是要保持健康的材料,只有食材健康,其他的都會隨之而來應對。

Apr. 18th 2016

台灣旅遊

旅遊

台灣的阿裡山的風俗習慣依然保留著中國清朝等古代的風俗習慣,並且還擁有美麗的日月潭、花蓮海等等知名景點。

Apr. 20th 2016

金融管理人才

金融

一個成功的企業家往往也可以被稱之為半個金融學管理人才,在很多的優秀企業的老闆中,有很大一部分都是懂得金融管理的。